— Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization —
— SOLOSEC ® (secnidazole) 2g Oral Granules is an FDA-Approved Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —
— Net sales surpassed $20 million mark in FY 2025 — — Income from operations increased to $3.4 million in FY 2025 —
Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving beyond legacy models can drive progress in women’s health
Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) today announced the launch of the Say Vagina Store , expanding its groundbreaking Say Vagina campaign...
— PHEXX ® Poised to Become First and Only Hormone-Free Contraceptive Vaginal Gel Approved in UAE —
-- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Evofem Shareholders Did Not Approve the Merger with Aditxt --
— First ex-U.S. Regulatory Filing for SOLSOEC ® —
SAN DIEGO , Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely...